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After the bite of a malaria-infected mosquito, the Plasmodium 
sporozoite infects liver cells and produces thousands of mero-
zoites, which then infect red blood cells, causing malaria. In 
malaria-endemic areas, several hundred infected mosquitoes can 
bite an individual each year, increasing the risk of superinfection. 
However, in infants that are yet to acquire immunity, superinfec-
tions are infrequent. We have recently shown that blood-stage 
parasitaemia, above a minimum threshold, impairs the growth of a 
subsequent sporozoite infection of liver cells. Blood-stage parasites 
stimulate the production of the host iron-regulatory factor hepci-
din, which redistributes iron away from hepatocytes, reducing the 
development of the iron-dependent liver stage. This could explain 
why Plasmodium superinfection is not often found in young non-
immune children. Here, we discuss the impact that such protection 
from superinfection might have in epidemiological settings or in 
programmes for controlling malaria, as well as how the induction 
of hepcidin and redistribution of iron might influence anaemia and 
the outcome of non-Plasmodium co-infections.
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Malaria today
Malaria infection is still a major scourge in the developing world, 
although there has been a gradual decrease in the number of deaths 
in the past ten years, and more than ten countries were able to reduce 
malaria cases by 50% (WHO, 2010). This is believed to be a response 
to a global movement, as proposed by Melinda Gates in 2007, 
towards the ambitious goal of malaria eradication. Nevertheless, 
malaria elimination will clearly not be reached with the available 
tools, especially in areas of moderate to high transmission (MalERA, 
2011). Thus, it remains of the greatest importance to better 
understand the biology of the causative agent of the disease—the 
protozoan parasite Plasmodium—and to delineate its complex rela-
tionships with human populations and the many species of mosquito 
by which it is transmitted. This is critical to establish the determinants 
of endemicity and transmission dynamics and to envisage new and 
better ways to fight malaria.
Plasmodium and its hosts
The three main players of a malaria infection—human (or other ver-
tebrate hosts), parasite and mosquito—have been known for more 
than a century. Nevertheless, the exact details of the Plasmodium 
life cycle and its needs, as well as the host and vector molecules 
that contribute to or fight infection are still not well understood. 
Plasmodium takes many forms during its life cycle, shifting between 
invasive and replicative stages both in the vertebrate host and in 
the anopheline vector. Infection starts during a blood meal, when 
an anopheline mosquito deposits Plasmodium sporozoites into the 
dermis of the host. Sporozoites use their capacity to traverse host 
cells to reach the circulation, where they travel to the liver, and to 
exit the liver sinusoids towards the hepatocyte, where each para-
site will develop and replicate into thousands of new merozoites 
(reviewed in Prudencio et al, 2006). These are then released into the 
bloodstream to infect red blood cells (RBCs) during several cycles of 
asexual replication, leading to the onset of disease. Occasionally, 
some parasites differentiate into sexual erythrocytic stages, originat-
ing female or male gametocytes that, after a subsequent blood meal, 
reach a mosquito’s midgut. Here, fertilization of gametes occurs 
forming ookinetes and, later, sporozoite-containing oocysts. These 
invade the mosquito salivary glands and restart the cycle at the next 
blood meal (Fig 1).
Malaria endemicity—the risk of re-infection
The intensity of malaria transmission can range from unstable epi-
demic transmission to high perennial transmission, and can be 
characterized by 100-fold differences in entomological measures 
of transmission (or entomological inoculation rates, EIRs). In regions 
of high malaria transmission, individuals can be exposed to sev-
eral hundred infected mosquito bites per year (Robert et al, 2003). 
In such regions, mosquitoes repeatedly transmit Plasmodium spo-
rozoites into individuals who already have Plasmodium parasites 
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from a previous infection, generating a risk of superinfection. This 
phenomenon occurs when single individuals host more than one 
Plasmodium species, or different genotypes of the same Plasmodium 
species, infecting RBCs (Babiker et  al, 1991; Bruce et  al, 2000; 
Richie, 1988). Although these mixed infections can be easily 
explained by consecutive infectious bites, an alternative explana-
tion proposed by Beier in 1988 is that they originate from a single 
infectious bite from one mosquito infected with more than one 
Plasmodium species or genotype (Beier et al, 1988). Nevertheless, 
it is well established that Plasmodium mixed infections more often 
occur in areas of high transmission (Mayor et al, 2003; Molineaux 
& Gramiccia, 1980; Owusu-Agyei et al, 2002; Sama et al, 2006), 
suggesting that the risk of superinfection generally originates from 
consecutive infectious bites.
Studies on superinfection have concentrated on the interactions 
between different genotypes or species of Plasmodium that infect 
RBCs, and several putative interactions have been described (Richie, 
1988). A longitudinal study in Papua New Guinea by Bruce and 
Day showed oscillatory peaks of infection with no coincidence of 









Fig 1 | Plasmodium life cycle. (A) During a blood meal, an anopheline mosquito injects Plasmodium sporozoites into the host dermis. (B) After reaching a blood 
vessel, sporozoites travel to the liver where—after traversing several hepatocytes—they invade a final one. (C) After asexual replication and development inside the 
hepatocyte, merozoites are released into the bloodstream. (D) Merozoites infect red blood cells during cycles of asexual replication. (E) Occasionally, replication 
cycles originate female and male gametocytes. (F) Through another blood meal, a mosquito ingests gametocytes into its midgut. (G) Fertilization of gametes 
occurs in the mosquito midgut with the formation of ookinetes and later the oocysts. (H) Sporozoites released from the oocyst migrate to the salivary gland of the 
mosquito and are released during the next blood meal.
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the Brazilian Amazon proposed that P. vivax reduces the severity of 
P. falciparum malaria (Lorenzetti et al, 2008. Other studies suggested 
that acute P. falciparum infection suppresses P. vivax parasitaemia, 
which increased to detectable levels after treatment (Looareesuwan 
et al, 1987; Snounou & White, 2004). Along these lines, McKenzie 
and Bossert made the interesting observation that fewer mixed- 
species infections than expected on the basis of the product of indi-
vidual species prevalences were observed in areas where P. vivax and 
P. falciparum coexist (McKenzie & Bossert, 1997). Nevertheless, an 
important but unexplained feature of the epidemiological studies is 
that concurrent carriage of various parasite genotypes at low asymp-
tomatic parasitaemias is only frequently seen in older, semi-immune 
children (Mayor et al, 2003; Molineaux & Gramiccia, 1980; Owusu-
Agyei et al, 2002; Sama et al, 2006). Why, then, is superinfection not 
frequently observed in younger, less immune children, who ought to 
be prone to sequential infections?
The sequence of events, from Plasmodium deposition and pas-
sage through the skin, followed by growth in hepatocytes and inva-
sion of erythrocytes is probably perturbed in high transmission areas, 
with new infections occurring in individuals harbouring parasites 
from previous infections. In these situations, the balance between 
the roles of host and pathogen—which have evolved towards ensur-
ing the survival of the host and the successful transmission of the 
pathogen—might be disturbed, raising the possibility of secondary 
interactions between the parasite and the parasitized host.
Having that in mind, we recently analysed the impact of an 
ongoing blood-stage infection on a subsequent liver infection. By 
using rodent models of malaria infection, we showed that ongoing 
blood-stage infections impair the growth of subsequently inoculated 
Plasmodium sporozoites such that they become growth-arrested 
in liver hepatocytes and fail to develop into blood-stage parasites 
(Portugal et  al, 2011). This impairment, caused by an ongoing 
blood-stage infection on the establishment of a Plasmodium liver 
infection, is independent of the Plasmodium species, transient and 
only occurs above a certain threshold of blood parasite density. This 
resembles a quorum-sensing mechanism described for bacteria, by 
which the blood stage is able to protect its niche from the threat of 
superinfection (Portugal et al, 2011).
Protection of young nonimmune children
Epidemiological studies from highly endemic areas consistently 
show that the concurrent carriage of various parasite genotypes at 
low asymptomatic parasitaemias is frequently seen in older chil-
dren but rarely seen in younger ones (Mayor et al, 2003; Molineaux 
& Gramiccia, 1980; Owusu-Agyei et al, 2002; Sama et al, 2006). 
In addition, the incidence of infection initially increases with age 
in young children before it declines as a result of acquired immu-
nity (Molineaux & Gramiccia, 1980; Sama et al, 2006). Can the 
observations made in mice—in which ongoing malaria blood-stage 
infections impair the establishment of new Plasmodium liver-stage 
infections—explain the low frequency of superinfections in young 
children? By using a simple agent-based model, we showed that 
threshold-density-dependent inhibition of new liver-stage infec-
tions alone can explain the changes in infection risk and complex-
ity of infections in young individuals observed in the field (Fig 2; 
Portugal et al, 2011).
Notably, modelling showed that this effect is dependent on the 
transmission intensity and is most prominent under moderate-to-
high transmission settings, as observed in epidemiological studies. 
This strongly suggests that the probability of a new Plasmodium 
infection occurring in humans is also dependent on the level of the 
peripheral blood parasitaemia.
Prevention of superinfection by ongoing blood-stage infec-
tions might have direct implications in host protection. The first 
Plasmodium in the blood protects its niche, possibly trying to 
ensure transmission on a first-come–first-served basis. Thus, the host 
immune system would only have to fight one circulating parasite, 
raising its chances of eliminating the circulating infected RBCs and 
clearing infection, thereby increasing the host’s chances of survival. 
This is particularly relevant for nonimmune individuals—the young 
ones in endemic regions. In older, semi-immune children, the risk 
of severe disease decreases and, as circulating parasitaemia is also 
lower, the complexity of blood-stage infections increases. Indeed, it 
has also been reported that superinfections are much more frequently 
observed among asymptomatic carriers—who have lower periph-
eral blood parasitaemias and thus are probably below our proposed 
threshold of protection—than in clinical cases (al-Yaman et al, 1997). 
Plasmodium has co-evolved with mammals for millions of years, 
and mechanisms such as this one, of protection from superinfection, 
seem to have been selected to benefit both the host and the incum-
bent pathogen by maintaining parasite density at levels that are not 
life threatening before acquired immunity takes up its role.
Young, semi-immune children (< 6 years old)
Immune children and adults (> 6 years old)
Hepatocyte
Fig 2 | Parasite‑dependent protective effect over age and time. Young children 
often have high levels of blood‑stage parasitaemia. When these children are 
re‑infected with sporozoites, little replication or development of parasites 
happens in the liver, inhibiting superinfection. The blood parasitaemia of an 
infection decreases with increasing age. Infected individuals become susceptible 
to further infections only once parasite densities fall below a critical threshold, 
raising the probability of superinfection.
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Superinfection protection and acquired immunity
Naturally acquired immunity to malaria was initially described 
almost 100 years ago (reviewed in Doolan et  al, 2009) and has 
been greatly debated. It is dependent on constant exposure to the 
Plasmodium parasite and on the degree of exposure. Nevertheless, 
re-infections and the great impact that an ongoing blood-stage 
infection has on a subsequent sporozoite infection have never 
been taken into consideration when studying the establishment of 
acquired immunity against Plasmodium. Although an early human 
study looked at how sequential Plasmodium inoculations could 
lead to multiple infections (Boyd, 1939), the possibility that the liver 
stage of infection could be modulated by the presence of another 
infection and contribute to acquisition of immunity was not defini-
tively explored. The inhibition of Plasmodium liver-stage growth 
of re-infected individuals might be acting as a live attenuated vac-
cine, promoting protection in endemic populations. In addition, 
the number of liver infections would be higher than the number of 
episodes of blood-stage infections, boosting the immune response 
to the liver stage without exposing the host to an extra blood-
stage infection. This could possibly contribute to the faster acqui-
sition of immunity and protection from severe disease, and both, 
co incidently, are associated with high Plasmodium transmission 
rates (Okiro et al, 2009; Snow & Marsh, 2002). It is therefore tempt-
ing to speculate that re-infection might also have a role in naturally 
acquired immunity.
Liver-stage-specific, naturally acquired immunity is not believed 
to be strong enough or acquired fast enough to provide protection in 
endemic populations (Marsh & Kinyanjui, 2006). Nevertheless, the 
infection of both humans and mice with Plasmodium sporozoites 
followed by chloroquine treatment—which abrogates the estab-
lishment of blood stages—protects individuals from subsequent 
infections (Belnoue et  al, 2008; Roestenberg et  al, 2009, 2011). 
Notably, vaccine development efforts have invested significantly 
in pre-erythrocytic immunization and proven efficient in render-
ing protection for variable periods of time. Indeed, the use of either 
attenuated forms of the parasite (Clyde, 1975; Waters et al, 2005) 
or live sporozoites (Roestenberg et al, 2009, 2011) can completely 
protect humans from malaria infections.
On the other hand, blood stages could suppress immune 
responses against liver-stage immunity, as blood-stage infec-
tion was shown to reduce the number of CD8+ T cells produced 
after irradiated sporozoite immunization (Ocana-Morgner et  al, 
2003). The impairment of Plasmodium liver infection by an ongo-
ing blood-stage malaria infection occurs in the absence of T cells 
(Portugal et al, 2011), but it is unclear what would happen after 
several infections, when acquired immunity would play a stronger 
role and other interactions could occur between these two stages 
of Plasmodium infection.
Undoubtedly, population-based studies of malaria-endemic areas 
and highly controlled experimental model systems will be decisive 
for the full understanding of the relevance of superinfection control 
in naturally acquired immunity to malaria.
The importance of iron for Plasmodium development
To understand how the inhibition of the liver stage by blood-
stage parasitaemia might have an impact on infection dynamics 
in malaria-endemic regions, the molecular basis of the phenom-
enon must be elucidated. The strain-independence and species-
independence of the effect, as well as its rapid kinetics, suggest that 
adaptive immunity is not involved, and this was confirmed experi-
mentally (Portugal et al, 2011). Both the number and size of exo-
erythrocytic forms are reduced during inhibition of the liver stage, 
suggesting that nutrient limitation might be involved. Almost all 
forms of life use iron in processes such as DNA synthesis, oxygen 
carriage and generation of ATP; iron is needed for growth and pro-
liferation (Schaible & Kaufmann, 2004). Plasmodium is no excep-
tion, and the importance of iron for parasite growth has been clear 
for the past 30 years. A seminal study showed that feeding patients 
after hospital admission during famine led to an early increase in 
serum iron and transferrin saturation that often preceded attacks 
of malaria and parasitaemia (Murray et al, 1975). Similarly, parasi-
taemia increased in Wister rats after intramuscular injection of iron, 
which also led to raised transferrin saturation (Murray et al, 1975). 
The effect of iron supplementation on malaria has been a subject 
of much debate, especially after the recent Pemba trial, in which 
prophylactic supplementation of preschool children with iron and 
folic acid in a population with high rates of malaria resulted in an 
increased risk of severe disease and death (Prentice et  al, 2007; 
Sazawal et al, 2006).
The need for iron during parasite replication has been explored 
in several studies, beginning with work by Scheibel and Adler using 
the Fe3+ chelator desferrioxamine (Scheibel & Adler, 1980, 1981, 
1982). Desferrioxamine has also been used to inhibit the growth of 
P. falciparum in RBCs in vitro; the removal of available iron caused 
a block in schizogony (Raventos-Suarez et al, 1982). Subsequent 
studies found that desferrioxamine inhibited the growth of blood-
stage parasitaemia in mice (Fritsch et al, 1985), primates (Pollack 
et  al, 1987) and humans (Bunnag et  al, 1992; Gordeuk et  al, 
1992a). However, desferrioxamine is not a good potential drug for 
wide use in the context of malaria owing to its poor membrane 
permeability and absorption when given orally, a short half-life in 
plasma, and a slow-to-develop antimalarial effect (Cabantchik et al, 
1996). Perhaps for these reasons, desferrioxamine did not reduce 
mortality in clinical trials (Thuma et al, 1998a), despite some early 
promise (Gordeuk et al, 1992b), nor did the orally active iron che-
lator deferiprone (Thuma et al, 1998b). Nevertheless, the particu-
lar sensitivity of Plasmodium blood-stage growth to iron chelators, 
noted by Glickstein and colleagues among others (Glickstein et al, 
1996), means that the iron chelation approach might be beneficial, 
and further iron-binding molecules aimed at halting Plasmodium 
growth are being developed (Pradines et  al, 2006; Rotheneder 
et al, 2002). One additional factor to bear in mind, however, is that 
the potent antimalarial artemisinin requires iron for its action—so 
that co-administration with iron chelators is probably ill-advised 
(Meshnick et al, 1993; Weinberg & Moon, 2009).
Plasmodium proliferates prodigiously in hepatocytes 
(Prudencio et al, 2006). The rate of parasite growth within hepa-
tocytes exceeds that within RBCs, and such rapid cell division 
requires iron. Accordingly, iron loading of mice promotes the 
development of Plasmodium yoelii, and iron supplementation of 
hepatocyte cultures increases parasite numbers in  vitro (Goma 
et  al, 1996). In addition, iron deficiency might reduce para-
site growth both in animals and in cultured hepatocytes (Goma 
et al, 1995; Loyevsky et al, 1999). Together, these data indicate 
that Plasmodium replication in both the liver and the erythro-
cytes requires iron. The precise source of iron and the molecular 
mechanisms by which Plasmodium acquires iron from its host cell 
remain unclear (see Sidebar A).
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Hepcidin controls iron availability and distribution
Iron availability in vivo clearly has important effects on Plasmodium 
growth, as it does in all other forms of life. Iron transport and homeo-
stasis in mammals is under the control of the iron regulatory hormone 
hepcidin, a circulating 25 amino acid peptide (Ganz & Nemeth, 
2011). The levels of iron in humans are normally kept in balance 
through the regulation of intestinal dietary absorption, through which 
about 1 mg of iron is acquired per day. About 20–25 mg iron are 
recycled daily by macrophages, which ingest senescent RBCs, enzy-
matically release iron from haemoglobin and export iron back into 
the serum. Both the duodenal enterocytes and the macrophages of 
the reticulo endothelial system release iron through the only known 
mammalian iron exporter protein ferroportin (Abboud & Haile, 
2000; Donovan et al, 2000, 2005; McKie et al, 2000), a process that 
is targeted by hepcidin. The accumulation of iron increases hepcidin 
synthesis by the liver (Pigeon et al, 2001), which is released into the 
circulation and binds to ferroportin. The hepcidin–ferroportin com-
plex is then internalized and degraded, ceasing iron export (Nemeth 
et al, 2004a). Hence, increases in hepcidin synthesis lead to reduced 
iron absorption and inhibited iron recycling, restoring equilibrium. 
Genetic defects that disrupt this autoregulatory feedback loop lead 
to clinically important disorders of metabolism. For example, heredi-
tary haemochromatosis is caused by mutations that reduce hepcidin 
synthesis (Bridle et al, 2003; Ganz & Nemeth, 2011) or that con-
fer hepcidin resistance to variants of ferroportin (Drakesmith et al, 
2005). As a result, ferroportin activity is uninhibited and dietary iron 
absorption is chronically increased. Reduced hepcidin can also be 
caused by an increased erythropoietic drive; a signal is believed to 
originate from highly activated bone marrow that acts on the liver to 
suppress hepcidin levels (Ganz & Nemeth, 2011; Tanno et al, 2007). 
The iron accumulation that results from low hepcidin can be toxic, 
as increased serum iron and total body iron levels lead to iron depo-
sition in parenchymal tissues, especially hepatocytes. Conversely, 
genetic defects that lead to increased hepcidin and block ferro portin 
can lead to iron-deficiency anaemia (Finberg et  al, 2008) caused 
by a reduction of dietary iron absorption and sequestration of iron 
in reticuloendothelial macrophages, including those of the spleen. 
In this condition, serum iron is very low, and the flow of iron to 
the bone marrow—where it is needed for incorporation in haemo-
globin—is restricted. Therefore, changes in hepcidin synthesis affect 
both the amount of iron and its tissue distribution within the body. 
Because different pathogens target particular tissues—or, as in the 
case of Plasmodium, the same pathogen infects specific cell types 
as its life-cycle progresses—fluctuations in hepcidin levels have 
the potential to change iron availability during infections. As iron is 
important for the growth of pathogens, this suggests that hepcidin lev-
els could influence the course and outcome of infections. However, 
hepcidin is not the only factor that influences the availability of 
iron to pathogens. Within cells, iron is present in different compart-
ments, such as stored in ferritin or loosely bound to chaperones in the 
cytoplasm—known as the ‘labile iron pool’. The relative amounts of 
iron in these intracellular locations are also important in determin-
ing its availability for specific pathogens, which in turn have evolved 
the capacity to scavenge iron from different compartments (Byrd & 
Horwitz, 1991; Nairz et al, 2007). Exactly how hepcidin influences 
the intracellular distribution of iron in different cell types remains to 
be determined, but there are studies that suggest that high hepcidin 
and low ferroportin activity increase iron storage within ferritin in 
macrophages (Ganz & Nemeth, 2011).
Hepcidin in Plasmodium infections
Increased hepcidin levels have been found in blood-stage malaria 
infections of P. falciparum and P. vivax (de Mast et al, 2009a,b, 2010; 
Howard et al, 2007), and a potential role of hepcidin in the aetiol-
ogy of malarial anaemia—an important aspect of malarial illness—
has been discussed. Haemolysis, sequestering of erythrocytes and 
increased erythrophagocytosis all contribute to anaemia, but an 
additional factor to consider is the inability of erythropoiesis to keep 
pace with RBC loss (Lamikanra et al, 2007; Rencricca et al, 1974). 
Dyserythropoiesis also occurs in malaria despite generally high 
erythropoietin levels; the response to erythropoietin is blunted prob-
ably due to the action of haemozoin and cytokines (Casals-Pascual 
et  al, 2006; Lamikanra et  al, 2007). This lack of a strong erythro-
poietic drive might mean that the signals normally produced by an 
active bone marrow, which suppress hepcidin, are not synthesized 
during malaria. This failure to suppress hepcidin allows inflammatory 
cytokines—possibly including interleukin-6 (de Mast et al, 2009b; 
Nemeth et  al, 2004b)—to further increase hepcidin levels, which 
exacerbates dyserythropoiesis by sequestering iron in macrophages. 
Thus, a vicious cycle could arise, in which loss of erythrocytes during 
malaria leads to an increase in hepcidin, rather than to the decrease 
that is seen in other situations of blood loss, which in turn means not 
enough iron is available to support RBC generation (Fig 3). An alter-
native, or additional, view of the increase in hepcidin is that it is a 
host response to infection. From this perspective, high hepcidin levels 
and subsequent lowering of RBC production and iron content could 
possibly represent an attempt by the host to reduce the number of 
available targets and the amount of available iron for Plasmodium. In 
such a scenario, hepcidin would function as an innate immune mol-
ecule (Armitage et al, 2011) that might help to control parasitaemia 
before the development of adaptive immune responses. More work is 
clearly needed to clarify these issues (see Sidebar A).
Hepcidin and Plasmodium liver-stage inhibition
What about the role of hepcidin in the inhibition of superinfec-
tion? It is well established that low levels of hepcidin lead to iron 
accumulation in hepatocytes, whereas macrophages are rela-
tively spared, as observed, for example, in the iron overloading 
disorder hereditary haemochromatosis (Pietrangelo, 2010). By 
contrast, high hepcidin levels lead to increased reticulendothelial 
iron deposition, and mice overexpressing hepcidin have rela-
tively reduced levels of liver iron (Gardenghi et  al, 2010). We 
found that blood-stage Plasmodium infections caused an iron 
redistribution effect: more non-haem iron was found in the spleen 
Sidebar A | In need of answers 
(i)  Do young, nonimmune children living in endemic areas of malaria  
 have a natural protection system from superinfection? Are hepcidin  
 and iron the critical factors to protect individuals from   
 superinfection? What other factors might be involved?
(ii)  What are the molecular mechanism and the impact of hepcidin  
 upregulation for blood‑stage infections and anaemia? And for  
 Plasmodium transmission?
(iii)  How do malaria‑induced changes in hepcidin and iron influence  
 susceptibility to co‑infections?
(iv)  How is iron acquired by Plasmodium during either liver or blood  
 stages of infection?
(v)  Do hepcidin and iron levels influence relapse from P. vivax   
 (hypnozoite activation)?
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and less in hepatocytes. This effect would be consistent with an 
increase in hepcidin mRNA, which was indeed observed in the liv-
ers of mice with ongoing blood-stage parasitaemia. Earlier studies 
discussed above had hinted that the liver stage of Plasmodium 
infection is, similarly to the blood stage, iron-dependent. This is fur-
ther supported by in vitro and in vivo experiments showing that iron 
chelation reduces exoerythrocytic forms size and liver parasite 
load, and iron supplementation increases Plasmodium develop-
ment in hepatoma cultures and in intact mice (Portugal et al, 2011). 
Hepcidin inhibits the growth of the liver stage by limiting the access 
of proliferating parasites to iron, as shown by increasing hepcidin 
using three experimental methods: injection of hepcidin peptide, 
infection with hepcidin-expressing recombinant adenovirus and 
use of transgenic mice engineered to overexpress hepcidin. In all 
three conditions, the development of liver-stage Plasmodium infec-
tion was significantly reduced. Could the increased hepcidin 
caused by blood-stage infections be responsible for the inhibition 
of liver-stage infections? This is probably the case, as clearance of 
an ongoing blood-stage infection with chloroquine returned hepci-
din mRNA to usual levels and allowed the normal development of a 
secondary liver infection. In addition, the waxing and waning of 
P. chabaudi blood-stage infections—which are naturally cleared in 
mice—correlated with a rise and then fall to baseline of hepcidin 
levels; secondary liver-stage infections could only develop in 
P. chabaudi-infected mice once hepcidin expression had returned 
to its normal levels. Injecting increasing numbers of parasitized 
RBCs caused a corresponding increase in liver hepcidin mRNA; an 
increase of RBCs above 0.15% parasitaemia and of hepcidin 
expression more than 3.3-fold inhibited the development of a liver-
stage infection initiated by injection of sporozoites. Importantly, 
this hepcidin upregulation renders levels similar to those found in 
the transgenic mice in which liver infection was also inhibited 
(Fig 4). Thus, hepcidin is sufficient to inhibit the development of the 
liver stage, and its levels correlate with the inhibition of the liver 
stage mediated by an ongoing blood-stage infection. Together, these 
experiments strongly suggest that iron redistribution caused by hep-
cidin is a key factor that can determine the outcome of liver 
Plasmodium infection acting independently of immunity. This pro-
vides new insights as to how the availability of a nutrient might 
have an impact on transmission dynamics and disease protection in 
endemic settings, in which iron deficiency, anaemia and oral iron 
supplementation are commonplace.
Co-infections of Plasmodium and other pathogens
The profound effect of hepcidin and iron on Plasmodium liver 
infection raises the question of whether the incidence and/or 
severity of infection by other pathogens are altered by the iron 
redistribution caused by malaria (see Sidebar A). In principle, 






























Fig 3 | Malaria, hepcidin and anaemia. (A) In a healthy individual, loss of red blood cells (RBCs)—for example, by haemorrhage—leads to a hypoxia‑induced increase 
in erythropoietin (EPO) production and a higher erythropoietic drive. Through mechanisms that are not fully understood, hepcidin synthesis by the liver is also 
reduced, increasing iron availability for incorporation into haemoglobin, and enabling recovery from anaemia. (B) Malaria infection also leads to a loss of RBCs, but 
causes an increase in hepcidin. Iron is sequestered in macrophages and is therefore not available for an efficient bone marrow response. In addition, the haemozoin 
released by replicating parasites and cytokines produced during the inflammatory response to infection further inhibits erythropoiesis. 
Fig 4 | Rodent models used to study the role of hepcidin and iron in primary Plasmodium infections and superinfection. (A) During blood‑stage infection, hepcidin 
upregulation inhibits liver infection, suppressing Plasmodium superinfection. (B) Reduction of hepcidin back to levels in non‑infected mice, by using chloroquine 
to treat blood‑stage parasitaemia, allows secondary sporozoite infection to progress to blood infection. (C) Increased hepcidin levels in the absence of blood‑stage 
infection—by using transgenic mice that overexpress hepcidin or through the inoculation of hepcidin peptide or hepcidin‑expressing adenovirus into wild‑type  
mice—impair sporozoite liver infection. 
◀







EMBO reports VOL 12 | NO 12 | 2011 ©2011 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION1240 
reviews review
co-infection by macrophage-tropic and iron-requiring microbes 
might be favoured by the presence of blood-stage Plasmodium par-
asites, as hepcidin induction during blood-stage infection increases 
levels of macrophage iron retention. Infection of non-typhoi-
dal Salmonella (NTS) could fit into this simple scheme in many 
respects. NTS multiplication within macrophages is iron-depend-
ent, and changes in the expression of genes that regulate iron alter 
bacterial growth (Nairz et al, 2007). In particular, the hepcidin–fer-
roportin axis influences Salmonella replication, as increased ferro-
portin expression reduces intracellular bacterial growth, an effect 
that is counteracted by exo genous hepcidin (Chlosta et al, 2006). 
Accordingly, mice injected with P.  yoelii nigeriensis have been 
shown to be more susceptible to Salmonella infection (Roux et al, 
2010). Haemolysis alone does not account for increased bacterial 
growth, suggesting that other factors might be important. Although 
not investigated in that study, a candidate for such a factor would 
be Plasmodium-induced hepcidin. In human populations, malaria 
seems to be a risk factor for NTS in children, and co-infections can 
be lethal (Mabey et al, 1987). Peaks of malaria and NTS infection 
coincide in areas where malaria transmission is seasonal, and NTS 
is particularly linked with severe malarial anaemia (Graham et al, 
2000; Mabey et al, 1987), which, in turn, is associated with higher 
parasitaemia and hepcidin. Finally, a decrease in the incidence 
of malaria in the Gambia was closely associated with a decline 
in the incidence of NTS (Mackenzie et al, 2010). Together, these 
studies suggest that Plasmodium blood-stage parasitaemia might 
promote and exacerbate NTS infection through the induction of 
hepcidin, causing an accumulation of iron within the cell type that 
Salmonella favours for replication—macrophages. Other aspects 
of host–pathogen interactions will clearly also be important for 
the outcome of disease, such as potential suppression of immune 
responses and the effects of anaemia, but the influence of iron on 
pathogen growth might be strong. Deleterious outcomes of other 
important infections including tuberculosis and HIV-1  are also 
associated with accumulation of iron in macrophages (Boelaert 
et al, 2007; de Monye et al, 1999), and therefore might potentially 
be exacerbated by Plasmodium. Studies on HIV-1  and malaria 
co-infections have often focused on the undoubted importance 
of virally induced immune deficiency on control of Plasmodium, 
but the effects of iron redistribution due to malaria might not be 
without consequence, as HIV-1 replication is iron-dependent 
(Drakesmith & Prentice, 2008).
New findings, new perspectives, more questions
If young, nonimmune individuals have a natural protection system 
from superinfection—which will be important to analyse in popula-
tions where Plasmodium is endemic (see Sidebar A)—the old con-
cern that reducing the risk of Plasmodium infection will necessarily 
lead to a decrease in the threat of severe malaria throughout life is 
emphasized once more (Garnham, 1949).
Examples such as that of Sri Lanka after the Global Malaria 
Eradication Program initiated in 1955 hint that there is a risk 
associated with reducing transmission without elimination. The 
resurgence of malaria when the intervention stopped gained epi-
demic proportions and the levels of mortality and morbidity were 
higher than those reported before the eradication programme 
(Wijesundera Mde, 1988). Recent results from intermittent pre-
ventive treatment of malaria in children indicate that this with 
sulphadoxine-pyrimethamine plus amodiaquine, although not 
associated with an increase in the prevalence of malaria infection, 
was associated with a small increase in the incidence of clinical 
malaria in the subsequent malaria transmission season (Dicko 
et al, 2011; Konate et al, 2011). Conversely, results from the pre- 
erythrocytic vaccine trial RTSS show that reducing Plasmodium 
liver load in children leads to a significant decrease in the severity 
of disease (Vekemans et al, 2009).
Further work towards fully understanding host–Plasmodium 
interactions, and the association between transmission and immu-
nity will be of major importance in defining malaria control inter-
ventions and predicting their outcome over time. Our knowledge 
about single malaria infections has increased greatly in the past 
decades, much due to the developments in systems biology and 
large-scale approaches and to the use of animal models. Infections 
should be studied—even in experimental models—as they appear 
in nature, in the presence of co-infections that might influence the 
next one directly or through its effects on the host, which could also 
have some impact on the primary infection. Such an approach has 
also been proposed by others (Boraschi et al, 2008). A recent report 
showing that a protozoan parasite can be infected by a virus, which 
contributes strongly to the harm caused to the host (Ives et al, 2011), 
highlights the complexity of host–pathogen interactions, and that 
unravelling such complexity is crucial to understanding infectious 
diseases. Similarly, the unveiling of an unexpected new relation-
ship between the liver and blood stages of Plasmodium infection has 
ramifications for strategies to eliminate malaria.
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